AzTrials
AzTrials

SilicosisSTARSSNCT05538299

Silicosis Treatment, Action, Screening and Surveillance in Rwanda Trials

An observational study of Silicosis and Silicotic Fibrosis (Massive) of Lung, run by Samuel Hatfield at 1 site in Rwanda.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Silicosis is the most prevalent occupational lung disease in low- and middle-income countries (LMICs) with "tens of millions" estimated to suffer from the disease according to the World Health Organization (WHO). Read more about this study

Who is it for?
Any age
What is being tested?
questionnaire, KAP
How many people
995 participants
Where
1 siteRwanda
Study dates
31 Jul 2022to 31 Jul 2023
How long will I take part?
1 Year
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: All eligible mine workers in Kayonza District in four sectors including: Rwinkwavu, Murama, Ruramira, and Mwiri sectors, located in the Rwinkwavu DH catchment area will be included in the study. Those miners with potential risk for RCS exposure, including those who handle mining either underground or above ground will be included. People who work in WOLFRAM administration (office) and never directly touch mines will not be included.

Who may be able to join

  • Miners with greater than 1 year of potential exposure to respirable crystalline silica within the defined catchment area of the study

Who cannot join

  • non-mining (administrative, low risk of exposure) workers within the WOLFRAM (mining company) catchment area

Trial locations and contacts

1 site in 1 country.

Robert Tumusime contact

250788597448

rtumusime@pih.org

Samuel Hatfield contact

808-497-2509

shatfields@pih.org

Rwanda1 site, 1 recruiting
  • Rwinkwavu District Hospital

    Rwinkwavu, Kayonza

    Robert Tumusime, rtumusime@pih.org

    Innocent Kamali

    Recruiting

Other trials in Rwanda

About this study

Official title: Silicosis Prevalence and Related Knowledge, Attitudes and Practices Among Mine Workers in Rural Rwanda

Silicosis is the most prevalent occupational lung disease in low- and middle-income countries (LMICs) with "tens of millions" estimated to suffer from the disease according to the World Health Organization (WHO). To date, there is little published data on silicosis in LMICs and the burden of silicosis in Rwanda has not been well-defined. Silicosis among local mine workers is a common reason for hospitalization and death at Rwinkwavu District Hospital, located in Rwanda's Kayonza District.

The objectives of this study are:

  1. To assess the prevalence of silicosis among workers in four mines located in the Kayonza District of Rwanda
  2. To adapt a validated screening tool testing in Dutch construction workers for Rwandan miners
  3. To implement an occupational health education program and assess the change of before and after intervention that target towards proper use of PPE and individual risk assessment in mine workers using knowledge-attitudes-practice tool
Read the detailed description

Based on the clinical experience of the investigators and their network, silicosis morbidity and mortality have been consistently encountered among Rwandans with dust and mining exposure, however Rwanda currently lacks an existing body of data on current silicosis prevalence and a surveillance system for ongoing monitoring and interventions. According to the WHO, disease surveillance programs should include periodic identification and collection of health information, evaluation and interpretation of the information, and reporting and interventions for the purpose of prevention. The goal of surveillance is to monitor the trends in disease incidence over time across a particular domain, define the magnitude or relative magnitude of a problem and target and evaluate interventions. Here, the investigators propose a study of silicosis-related data from mine workers in Rwanda's Eastern Province through the development of a silicosis surveillance and health education program at Rwinkwavu District Hospital.

Methodology:

Study setting:

This study will be conducted in four sectors (Rwinkwavu, Murama, Ruramira, and Mwiri) of Kayonza district in eastern Rwanda. There are 9 [Migera, Gihinga, Nyarunazi, Gahengeli, Gashushyi, Rutonde, Raveri, Bugambira, Rukira] mining sites in Rwinkwavu, Murama, Ruramira and Mwiri, and all mining activities in these sites are supervised by Wolfram Mining and Processing LTD. All these sectors are located in the Rwinkwavu District Hospital catchment area.

Study design:

This will be a combination of a cross-sectional study to determine the prevalence of silicosis and a pre- and post-design to assess the silicosis-related knowledge, attitudes and practices (KAP) among mining workers before and after the implementation of a health education program.

The study design will be cross-sectional study. There are three main objectives: silicosis prevalence; baseline silicosis-related knowledge, attitudes and practices (KAP); and the impact of occupational health education. A team of clinical and public health professionals affiliated with Partners In Health/Inshuti Mu Buzima and Rwinkwavu District Hospital will carry out the study with data collection assistance. The preparation phase will involve contacting and establishing agreements with stakeholders from key organizations including Rwinkwavu District Hospital, Wolfram Mining and Processing Ltd., University of Rwanda and Partners in Health/Inshuti Mu Buzima. This phase will involve training data collectors and recruiting study subjects. The study execution phase will firstly consist of a cross-sectional analysis of silicosis prevalence, adapting a validated silicosis questionnaire screening tool to the target study population and performing spirometry and chest radiography to all targeted miners [Suarthana, Eva, et al. "A Simple Diagnostic Model for Ruling Out Pneumoconiosis among Construction Workers." Occupational and Environmental Medicine, JSTOR]. This screening tool for ruling out occupational pneumoconiosis, and silicosis specifically, was developed by researchers in the Netherlands. The investigators will adapt and validate the use of this screening tool to Rwandan mine workers by comparing the screening results with objective spirometry and chest radiograph findings on all subjects who have spent at least one cumulative year working directly with mining products. Secondly, the execution phase will involve an analysis of existing silicosis related KAP and the delivery of targeted occupational health education to study subjects followed by a reassessment of knowledge and attitudes. The Investigators will perform initial education program and KAP survey at the time of questionnaire-based screening with re-assessment at 2-week time point. There are approximately 995 mine workers in the catchment area of this study and the investigators' goal is to try and involve all of these stakeholders. Baseline KAP survey will be done prior to this health education program on PPE, environmental controls and personal safety assessment and deployment of the screening questionnaire. Silicosis related KAP data will be collected by skilled data collectors after a two-week training program.

Study population:

All eligible mine workers in Kayonza District in four sectors including: Rwinkwavu, Murama, Ruramira, and Mwiri sectors, located in the Rwinkwavu DH catchment area will be included in the study. Those miners with potential risk for RCS exposure, including those who handle mining either underground or above ground will be included. People who work in WOLFRAM administration (office) and never directly touch mines will not be included.

Study sample:

For the aim to determine the prevalence of silicosis, The investigators used the single population proportion formula to calculate the required sample size. With the existing literature that silicosis prevalence among high-risk populations in LMICs may range between 30-50% [Trapido, A.S. et al (1998) Prevalence of occupational lung disease in a random sample of former mineworkers, Libode District, Eastern Cape Province, South Africa. American Journal of Industrial Medicine, Antão VC, Pinheiro GA, et al., High prevalence of silicosis among stone carvers in Brazil. Am J Ind Med. 2004], The investigators used the most conservative estimate of 50% for a maximum sample size, with a level of confidence of 95%, 0.8 power and a level of precision of +/- 10% - a sample of 189 individuals will be required. For the silicosis-related KAP part of this study, the investigators also used the most conservative estimate of 50%, a 95% confidence level, and a 0.8 power to detect a 20% difference from pre- to post-intervention. This gave us a required total sample size of 186 individuals (a minimum sample of 93 individuals will be required for the pre- and post-survey), however the required sample size would increase to 224 individuals (112 individuals in each survey) after accounting for a 20% non-response rate. The investigators estimate the study sample to be around 995 mine workers, so there will be ample participants to conduct this study.

The investigators' goal is to sample the complete mining population so as to obtain accurate prevalence of the full cohort of miners within the RDH catchment area, which may also allow us to detect asymptomatic disease in certain miners, and to enroll these patients in future surveillance programs. Additionally, validation of a screening questionnaire in Rwanda will allow us to deploy a low-cost tool in the rural health network to identify additional early cases of silicosis in the community

Being tested
questionnaire, KAP
Medical subject headings
Silicosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • questionnaire, KAPBehavioural

    Also called diagnostic

    Diagnostic studies including questionaire, CXR, spirometry, clinical assesment, occupational safety training

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Silicosis Prevalence

    Estimate Silicosis prevalence in the Eastern Province of Rwanda

    Measured: 6 months

Secondary outcomes (2)
  1. Questionnaire Validation

    Validate Questionnaire originated in Europe for use in occupational health screening in Rwanda

    Measured: 1 year

  2. Knowledge, Action, Prevelence

    Obtain data on knowledge, action and practice for individual, administrative and engineering controls for spread of silica dust in mines in Eastern Rwanda

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Sep 2022
  2. Study start31 Jul 2022
  3. Primary completion31 Dec 2022 (estimated)
  4. Study completion31 Jul 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Cross-sectional
Enrolment
995 participants (estimated)
Target duration
1 Year
IDs, dates and publications
ClinicalTrials.gov ID
NCT05538299
Sponsor's protocol ID
IMB-sil1
Acronym
STARSS
Status last verified
Sep 2022
First submitted
8 Sep 2022
Last updated
22 Sep 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Data will be shared publicly for further research involving silicosis 6-9 months following the completion of this trial

Publications

  • Suarthana E, Moons KG, Heederik D, Meijer E. A simple diagnostic model for ruling out pneumoconiosis among construction workers. Occup Environ Med. 2007 Sep;64(9):595-601. doi: 10.1136/oem.2006.027904. Epub 2007 Apr 4.

    PubMed 17409183

Questions about this trial

What is this clinical trial studying?

An observational study of Silicosis and Silicotic Fibrosis (Massive) of Lung, run by Samuel Hatfield at 1 site in Rwanda.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 22 Sep 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Rwanda. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Robert Tumusime (250788597448, rtumusime@pih.org), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Silicosis Prevalence (time frame: 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05538299, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Sep 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in